Extrahepatic manifestations of cholestasis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 17, Issue 9, 2002, Pages 938-948

  Glasova, Helena ^a   Beuers, Ulrich ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Cholestasis; Fatigue; Osteopenia; Osteoporosis; Pruritus

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID; CALCITONIN; CALCIUM; COLECALCIFEROL; COLESTYRAMINE; CONTRACEPTIVE AGENT; DIGOXIN; ESTROGEN; ETIDRONIC ACID; FLUORIDE SODIUM; LIDOCAINE; NALMEFENE; NALTREXONE; ONDANSETRON; OPIATE; OPIATE ANTAGONIST; OSTEOPROTEGERIN; PROPOFOL; RIFAMPICIN; SEROTONIN 3 ANTAGONIST; STATIN; THYROXINE; URSODEOXYCHOLIC ACID; VITAMIN D; VITAMIN K GROUP;

ALLERGY; CHOLESTASIS; CLINICAL FEATURE; DEPRESSION; DISEASE ASSOCIATION; EXERCISE; FATIGUE; FRACTURE; HORMONE SUBSTITUTION; HUMAN; LIFESTYLE; LIVER TRANSPLANTATION; METABOLIC BONE DISEASE; NEUROPSYCHIATRY; NEUROTRANSMISSION; OBSESSION; OSTEOMALACIA; OSTEOPENIA; OSTEOPOROSIS; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT; POSTMENOPAUSE; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; REVIEW; SEROTONINERGIC SYSTEM; SIDE EFFECT; SLEEP; STRESS; VITAMIN SUPPLEMENTATION;

EID: 0036379807     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2002.02717.x     Document Type: Review

References (127)

1. Trauner M, Meier PJ, Boyer JL. Mechanisms of cholestasis. N. Engl. J. Med. 1998; 339: 1217-27.
2. Kullak-Ublick GA, Beuers U, Paumgartner G. Hepatobiliary transport. J. Hepatol. 2000; 32 (Suppl. 1): 3-18
3. Krajnik M, Zylicz Z. Understanding pruritus. J. Pain Sympt. Manage. 2001; 21: 151-68.
4. Heathcote J. Update of primary biliary cirrhosis. Can. J. Gastroenterol. 2000; 14: 43-8.
5. Heathcote J. Management of primary biliary cirrhosis. Hepatology 2000; 31: 1005-13.
6. Gross CR, Malinchoc M, Kim WR et al. Quality of life before and after liver transplantation for cholestatic liver disease. Hepatology 1999; 29: 356-64.
7. Younossi ZM, Kiwi ML, Boparai N, Price LL, Guyatt G. Cholestatic liver diseases and health-related quality of life. Am. J. Gastroenterol. 2000; 95: 497-502.
8. Bergasa NV, Mehlman JK, Jones EA. Pruritus and fatigue in primary biliary cirrhosis. Bailliere's Clin. Gastroenterol. 2000; 14: 643-55.
9. Lucey MR, Neuberger JM, Williams R. Primary biliary cirrhosis in man. Gut 1986; 27: 1373-6.
10. Jones EA, Bergasa NV. The pruritus of cholestasis. Hepatology 1999; 29: 1003-6.
11. Raiford DS. Pruritus of chronic cholestasis. Q. J. Med. 1995; 88: 603-7.
12. Kam PCA, Tan KH. Pruritus: Itching for a cause and relief? Anaesthesia 1996; 51: 1133-8.
13. Bergasa NV, Jones EA. The pruritus of cholestasis: Potential pathogenic and therapeutic implications of opioids. Gastroenterology 1995; 108: 1582-8.
14. Swain MG. Pruritus and lethargy in the primary biliary cirrhosis patient. In: Neuberger J, ed. Primary Biliary Cirrhosis. Eastbourne: West End Studios, 1999; 75-81.
15. Jones EA, Bergasa NV. Evolving concepts of the pathogenesis and treatment of the pruritus of cholestasis. Can. J. Gastroenterol. 2000; 14: 33-40.
16. Ghent CN. Pruritus of cholestasis is related to effects of bile salts on the liver, not the skin. Am. J. Gastroenterol. 1987; 82: 117-18.
17. Kirby J, Heaton KW, Burton JL. Pruritic effect of bile salts. BMJ 1974; 4: 693-5.
18. Freedman MR, Holzback RT, Ferguson DR. Pruritus in cholestasis: No direct causative role for bile acid retention. Am. J. Med. 1981; 70: 1011-16.
19. Gittlen SD, Schulman ES, Maddrey WC. Raised histamine concentrations in chronic cholestatic liver disease. Gut 1990; 31: 96-9.
20. Quist RG, Ton-Nu HT, Lillienau J et al. Activation of mast cells by bile acids. Gastroenterology 1991; 101: 446-56.
21. Clements WD, O'Rourke DM, Rowlands BJ, Ennis M. The role of mast cell activation in cholestatic pruritus. Agents Actions 1994; 41: C30-1.
22. Rioux KP, Sharkey KA, Wallace JL, Swain MG. Hepatic mast cell hyperplasia in rats with secondary biliary cirrhosis. Hepatology 1996; 23: 888-95.
23. 3) receptor antagonists reduce experimentally induced itch? Inflamm. Res. 1997; 46: 412-16.
24. 3 receptor antagonist (tropisetron) is dependent on mast cell depletion: An experimental study. Exp. Dermatol. 1999; 8: 254-60.
25. Spivey JR, Jorgensen RA, Gores GJ, Lindor KD. Methionine-enkephalin concentrations correlate with stage of disease but not pruritus in patients with primary biliary cirrhosis. Am. J. Gastroenterol. 1994; 89: 2028-32.
26. Bergasa NV, Thomas DA, Vergalla J, Turner ML, Jones EA. Plasma from patients with the pruritus of cholestasis induces opioid receptor-mediated scratching in monkeys. Life Sci. 1993; 53: 1253-7.
27. Kiefel JM, Cooper ML, Bodnar RJ. Serotonin receptor subtype antagonists in the medial ventral medulla inhibit mesencephalic opiate analgesia. Brain Res. 1992; 597: 331-8.
28. Datta D, Sherlock S. Cholestyramine for long term relief of pruritus in jaundiced patients fed a bile acid sequestering resin. Gastroenterology 1966; 50: 323-32.
29. Rust C, Sauter G, Oswald M et al. Effect of cholestyramine on bile acid pattern and synthesis during administration of ursodeoxycholic acid in man. Eur. J. Clin. Invest. 2000; 30: 135-9.
30. Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomised trial. Gastroenterology 1988; 94: 488-93.
31. Bachs L, Pares A, Elena M, Piera C, Rodes J. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 1992; 102: 2077-80.
32. Galeazzi R. Rifampicin induced elevation of serum bile acids in man. Dig. Dis. Sci. 1980; 25: 108-12.
33. Souto EO, Jorgensen RA, Lindor KD. The natural history of pruritus in patients with PBC and effects of medical therapy. Hepatology 2000; 32: 42A.
34. Yerushalmi B, Sokol RJ, Narkewicz MR, Smith D, Karrerr FM. Use of rifampin for severe pruritus in children with chronic cholestasis. J. Pediatr. Gastroenterol. Nutr. 1999; 29: 442-7.
35. Riikonen S, Savonius H, Gylling H, Nikkila K, Tuomi AM, Miettinen TA. Oral guargum, a gel-forming dietary fiber, relieves pruritus in intrahepatic cholestasis of pregnancy. Acta Obstet. Gynecol. Scand. 2000; 79: 260-4.
36. Bachs L, Pares A, Elena M, Piera C, Rodes J. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet 1989; i: 574-6.
37. Bergasa NV, Talbot TL, Alling DN et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 1992; 102: 544-9.
38. Bergasa NV, Alling DN, Talbot TL et al. Effects of naloxone infusions in patients with the pruritus of cholestasis: A double-blind, randomised controlled trial. Ann. Intern. Med. 1995; 123: 161-7.
39. Wolfhagen FH, Sternieri E, Hop WC, Vitale G, Bertolotti M, Van Buuren HR. Oral naltrexone treatment for cholestatic pruritus: A double-blind, placebo-controlled study. Gastroenterology 1997; 113: 1264-9.
40. Terg R, Coronel E, Sorda J, Findor J. Oral naltrexone treatment for cholestatic pruritus: A randomized, double-blind, crossover study. Hepatology 2000; 32: 20A.
41. Bergasa NV, Schmitt JM, Talbot TL et al. Open-label trial of oral nalmefene for the pruritus of cholestasis. Hepatology 1998; 27: 679-84.
42. Bergasa NV, Alling DW, Talbot TL, Wells MC, Jones EA. Oral nalmefene therapy reduces scratching activity due to pruritus of cholestasis: A controlled study. J. Am. Acad. Dermatol. 1999; 41: 431-4.
43. Jones EA, Dekker LRC. Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis. Gastroenterology 2000; 118: 431-2.
44. Borgeat A, Mentha G, Wilder-Smith OH, Mentha G. Subhypnotic doses of propofol relieve pruritus associated with liver disease. Gastroenterology 1993; 104: 244-7.
45. Borgeat A, Mentha G, Savioz D, Wilder-Smith OH. Pruritus associated with liver disease: Propofol, a new therapeutic approach? Schweiz. Med. Wochenschr. 1994; 124: 649-50 (In German, abstract in English).
46. Schwörer H, Ramadori G. Treatment of pruritus: A new indication for serotonin type 3 receptor antagonists. Clin. Invest. 1993; 71: 659-62.
47. 3) receptor antagonists. Effectiveness of ondansetron. Pain 1995; 61: 33-7.
48. Muller C, Pongratz S, Pidlich J et al. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondasetrone: A randomised, placebo-controlled, double-blind cross-over trial. Eur. J. Gastroenterol. Hepatol. 1998; 10: 865-70.
49. Zylicz Z, Smiths C, Krajnik M. Paroxetine for pruritus in advanced cancer. J. Pain Sympt. Manage. 1998; 16: 121-4.
50. Lindor KD, Dickson ER, Baldus WP et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994; 106: 1284-90.
51. Pares A, Caballeria L, Rodes J et al. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: Results of a double-blind controlled multicentric trial. J. Hepatol. 2000; 32: 561-6.
52. Bergasa NV, Link MJ, Keogh M, Yaroslavsky G, Rosenthal RN, McGee M. Effect of bright-light phototherapy directed towards the eyes for the pruritus of cholestasis: Results of a pilot study. Hepatology 1998; 28: 443A.
53. Villamil AG, Bandi JC, Galdame O et al. Efficacy of lidocaine in the treatment of pruritus in patients with chronic cholestatic liver diseases. Hepatology 2000; 32: 168A.
54. Aaronson LS, Teel CS, Cassmeyer V. Defining and measuring fatigue. Image J. Nurs. Sch. 1999; 31: 45-50.
55. Witt-Sullivan H, Heathcote J, Cauch K, Blendis K, Ghent C, Katz A. The demography of primary biliary cirrhosis in Ontario. Can. Hepatol. 1990; 12: 98-105.
56. Huet PM, Deslauriers J, Tran A, Faucher C, Charbonneau J. Impact of fatigue on the quality of life of patients with primary biliary cirrhosis. Am. J. Gastroenterol. 2000; 95: 760-7.
57. Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF. Measuring the functional impact of fatigue: Initial validation of the fatigue impact scale. Clin. Infect. Dis. 1994; 18 (Suppl. 1): 79-83.
58. Cauch-Dudek K, Abbey S, Stewart DE, Heathcote EJ. Fatigue in primary biliary cirrhosis. Gut 1998; 43: 705-10.
59. Cauch-Dudek K, Heathcote EJ, Huterer N, Driver H, Shapiro C. Is disturbed sleep based on objective polysomnographic indicators a factor in the fatigue of patients with primary biliary cirrhosis? Hepatology 1998; 28: 543A.
60. Swain MG. Fatigue in chronic disease. Clin. Sci. 2000; 99: 1-8.
61. Prince MI, James OFW, Holland NP, Jones DEJ. Validation of a fatigue impact score in primary biliary cirrhosis: Towards a standard for clinical and trial use. J. Hepatol. 2000; 32: 368-73.
62. Jalan R, Gibson H, Lombard MG. Patients with PBC have central but no peripheral fatigue. Hepatology 1996; 24: 167A.
63. Demitrack MA, Dale JK, Straus SE et al. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J. Clin. Endocrinol. Metab. 1991; 73: 1224-34.
64. Vanderpool JRJ, Rosenthal NE, Chrousos GP, Wehr TA, Skwerer R, Kasper S. Abnormal pituitary-adrenal responses to corticotropin releasing hormone in patients with seasonal affective disorder: Clinical and pathophysiological implications. J. Clin. Endocrinol. Metab. 1991; 72: 1382-7.
65. Swain MG, Maric M. Defective corticotropin-releasing hormone mediated neuroendocrine and behavioural responses in cholestatic rats: Implications for cholestatic liver disease-related sickness behaviours. Hepatology 1995; 22: 1560-4.
66. Swain MG, Mogiakou MA, Bergasa NV, Chrousos GP. Facilitation of ACTH and cortisol responses to corticotropin-releasing hormone in patients with primary biliary cirrhosis. Hepatology 1994; 20: 146A.
67. Tilg H, Wimer A, Vogel W et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992; 103: 264-74.
68. Swain MG, Beck P, Rioux K, Le T. Augmented interleukin-1beta-induced depression of locomotor activity in cholestatic rats. Hepatology 1998; 28: 1561-5.
69. 2 release. Am. J. Physiol. 1995; 258: G404-9.
70. Plevris JN, Blair C, Cossar JA, Dollinger MM, O'Carroli RE, Hayes PC. Chronic fatigue is associated with increased interleukin-6 levels in patients with chronic liver disease. Hepatology 1997; 26: 583A.
71. Jones EA, Yurdaydin C. Is fatigue associated with cholestasis mediated by altered central neurotransmission? Hepatology 1997; 25: 492-4.
72. Swain MG, Le T. Chronic cholestasis in rats induces anhedonia and a loss of social interest. Hepatology 1998; 28: 6-10.
73. 1A receptor number and responsiveness in cholestatic rats. Brain Res. 2001; 892: 376-9.
74. 1A receptor agonists: Recent developments and controversial issues. Psychopharmacology 1995; 121: 1-26.
75. Swain MG, Maric M. Improvement in cholestasis-associated fatigue with a serotonin receptor agonist using a novel rat model of fatigue assessment. Hepatology 1997; 25: 291-4.
76. Jones EA. Relief from profound fatigue associated with chronic liver disease by long-term ondasetron. Lancet 1999; 354: 397.
77. Bergasa NV, Mehlman JK, Jones EA. Pruritus and fatigue in primary biliary cirrhosis. Bailliere's Clin. Gastroenterol. 2000; 14: 643-55.
78. Thornton JR, Losowsky MS. Opioid peptides and primary biliary cirrhosis. BMJ 1988; 297: 1501-4.
79. Sharpe M. Cognitive behaviour therapy for chronic fatigue syndrome. Am. J. Med. 1998; 105: 1045-95.
80. Watson JP, Jones DEJ, James OFW, Cann PA, Bramble MG. Oral antioxidant therapy for the treatment of primary biliary cirrhosis: A pilot study. J. Gastroenterol. Hepatol. 1999; 14: 1034-40.
81. Rouillard S, Lane N. Hepatic osteodystrophy. Hepatology 2001; 33: 301-7.
82. Pares A. Management of primary biliary cirrhosis: Osteoporosis. In: Lindor KD, Heathcote EJ, Poupon R, eds. Primary Biliary Cirrhosis: From Pathogenesis to Clinical Treatment. Dordrecht: Kluwer Academic Publishers, 1998; 92-101.
83. Stellon AJ, Webb A, Copston J, Williams R. Low bone turnover in primary biliary cirrhosis. 1987; 7: 137-42.
84. Cuthbert JA, Pak CYC, Zerwkh JE, Glass KD, Combers B. Bone disease in primary biliary cirrhosis: Increased bone resorption and turnover in the absence of osteoporosis or osteomalacia. Hepatology 1984; 4: 1-8.
85. Hay JE, Lindor KD, Wiesner RH, Dickson ER, Krom RAF, LaRusso NF. The metabolic bone disease of primary sclerosing cholangitis. Hepatology 1991; 14: 257-61.
86. Mitchison HC, Malcolm AJ, Bassendine MF, James OFW. Metabolic bone disease in primary biliary cirrhosis at presentation. Gastroenterology 1988; 94: 463-70.
87. Lindenthal B, Leuschner MS, Ackermann H, Happ J, Leurschner UF. Is primary biliary cirrhosis (PBC) in itself a risk factor for osteoporosis? Hepatology 2000; 32: 168A.
88. Newton JL, Rawlings D, Prince MI, James OFW, Bassendine MF, Jones DEJ. Osteoporosis is not a specific complication of primary biliary cirrhosis. J. Hepatol. 2000; 32: 128.
89. Thien V, Cheung AM, Girlan LM, Tonlinson G, Josse R, Heathcote J. Osteopenia and osteoporosis in primary biliary cirrhosis: Its prevalence and response to therapy. Hepatology 2000; 32: 173A.
90. Porayko MK, Wiesner RW, Hay JE et al. Bone disease in liver recipients: Incidence, timing, and risk factors. Transplant. Proc. 1991; 23: 1462-5.
91. Ormarsdottir S, Ljunggren Ö, Mallmin H, Brahm H, Lööf L. Low body mass index and use of corticosteroids, but not cholestasis, are risk factors for osteoporosis in patients with chronic liver disease. J. Hepatol. 1999; 31: 84-90.
92. Diamond T, Stiel D, Lunzer M, Wilkinson M, Roche J, Posen S. Osteoporosis and skeletal fractures in chronic liver disease. Gut 1990; 31: 82-7.
93. NIH Consensus Development Panel on osteoporosis prevention, diagnosis, and therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285: 785-95.
94. Pares A, Guanabens N, Alvarez L et al. Collagen type Iα1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis. Hepatology 2001; 33: 554-60.
95. Hunter D, de Lange M, Snieder H et al. Genetic contribution to bone metabolism, calcium excretion, and vitamin D and parathyroid hormone regulation. J. Bone Miner. Res. 2001; 16: 371-8.
96. Springer JE, Cle DE, Rubin LA et al. Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. Gastroenterology 2000; 118: 145-51.
97. Guanabens N, Pares A, Marinoso L et al. Factors influencing the development of metabolic bone disease in primary biliary cirrhosis. Am. J. Gastroenterol. 1990; 85: 1356-62.
98. Herlong HF, Recker RR, Maddrey WC. Bone disease in primary biliary cirrhosis: Histological features and response to 25-hydroxyvitamin D. Gastroenterology 1982; 83: 103-8.
99. Heubi JE Higgins JV, Argao EA, Sierra RI, Specker BL. The role of magnesium in the pathogenesis of bone disease in childhood cholestatic liver disease: A preliminary report. J. Pediatr. Gastroenterol. Nutr. 1997; 25: 301-6.
100. 2 inhibits apoptotic cell death of human osteoblasts induced by Fas, proteasome inhibitor, etoposide, and staurosporine. J. Lab. Clin. Med. 2000; 136: 181-93.
101. 2 for bone loss in patients with primary biliary cirrhosis. J. Hepatol. 2001; 35: 543-5.
102. Gallego-Rojo FJ, Gonzales-Calvin JL, Munoz Torres M, Mundi JL, Ferdandez-Perez R, Rodrigo-Moreno D. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 1998; 28: 695-9.
103. Janes CH, Dickson ER, Okazaki R, Bonde S, McDonagh AF, Riggs BL. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J. Clin. Invest. 1995; 95: 2581-6.
104. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorbtion. J. Bone Miner. Res. 2000; 15: 2-12.
105. Heaney RP, Vitamin D. How much do we need, and how much is too much? Osteoporos. Int. 2000; 11: 553-5.
106. Wolfhagen FH, van Buuren HR, Vleggaar FP, Schalm SW. Management of osteoporosis in primary biliary cirrhosis. Bailliere's Best Pract. Res. Clin. Gastroenterol. 2000; 14: 629-41.
107. Wolfhagen FHJ, van Buuren HR, den Ouden JW et al. Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study. J. Hepatol. 1997; 26: 325-30.
108. Guanabens N, Pares A, Monegal A et al. Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: Preliminary results after 2 years. Gastroenterology 1997; 113: 219-24.
109. Lindor KD, Jorgensen RA, Tiegs RD, Khosla S, Dickson ER. Etidronate for osteoporosis in primary biliary cirrhosis: A randomised trial. J. Hepatol. 2000; 33: 878-82.
110. Trautwein C, Possienke M, Schlitt HJ et al. Bone density and metabolism in patients with viral hepatitis and cholestatic liver diseases before and after liver transplantation. Am. J. Gastroenterol. 2000; 95: 2343-51.
111. Eastell R, Dickson ER, Hodgson SF et al. Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology 1991; 14: 296-300.
112. Hamburg SM, Piers DA, van den Berg AP, Slooft MJH, Haagsma EB. Bone mineral density in the long term after liver transplantation. Osteoporos. Int. 2000; 11: 600-6.
113. Sahota O, Fowler I, Blackwell PJ et al. A comparison of continuous alendronate, cyclical alendronate and cyclical etidronate with calcitriol in the treatment of postmenopausal vertebral osteoporosis: A randomised controlled trial. Osteoporos. Int. 2000; 11: 959-66.
114. Reeves HL, Francis RM, Manas DM, Hudson M, Day CP. Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation. Liver Transplant. Surg. 1998; 4: 404-9.
115. Crandall C. Risedronate. Arch. Intern. Med. 2001; 161: 353-60.
116. Olsson R, Mattsson LA, Obrant K, Mellstrom D. Estrogen-progestogen therapy for low bone mineral density in primary biliary cirrhosis. Liver 1999; 19: 188-92.
117. Pereira SP, Williams R. A controlled trial of transdermal hormone replacement therapy in primary biliary cirrhosis. Hepatology 1998; 28: 166A.
118. Haguenauer D, Welch V, Shea B, Tugwell P, Adachi JD, Wells G. Fluoride for the treatment of posmenopausal osteoporotic fractures: A meta-analysis. Osteoporos. Int. 2000; 11: 727-38.
119. Camisasca M, Crosignani A, Battezzati PM et al. Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis. Hepatology 1994; 20: 633-7.
120. Floreani A, Chiaramonte M, Gianini S et al. Longitudinal study on osteodystrophy in primary biliary cirrhosis and a pilot study on calcitonin treatment. J. Hepatol. 1991; 12: 217-23.
121. Floreani A, Zappala F, Fries W et al. A 3-year pilot study with 1,25-dihydroxyvitamin D, calcium, and calcitonin for severe osteodystrophy in primary biliary cirrhosis. J. Clin. Gastroenterol. 1997; 24: 239-44.
122. Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 1999; 282: 637-45.
123. Muchmore DB. Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects. Oncologist 2000; 5: 338-92.
124. Bekker PJ, Holloway D, Nalanishi A, Arrighi HM, Leese PT, Dunstan CR. The effect of a single dose of osteoprotegerin in postmenopausal women. J. Bone Miner. Res. 2001; 16: 348-60.
125. Jamal SA, Browner WS, Bauer DC, Cummings SR. Intermittent use of nitrates increases bone mineral density: The study of osteoporotic fractures. J. Bone Miner. Res. 1998; 13: 1755-9.
126. Sugiyama M, Kodama T, Konishi K, Abe K, Asami S, Oikawa S. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem. Biophys. Res. Commun. 2000; 271: 688-92.
127. Beuers U, Wiedmann KH, Kleber G, Fleig WE. Therapy of autoimmune hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis. Consensus of the German Society of Digestive and Metabolic Diseases. Z. Gastroenterol. 1997; 35: 1041-9.